Free Trial

Lantheus (LNTH) Competitors

Lantheus logo
$102.13 +0.13 (+0.13%)
As of 04:00 PM Eastern

LNTH vs. ONC, BNTX, TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, and QGEN

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Lantheus vs.

Beigene (NASDAQ:ONC) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.

Beigene has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

In the previous week, Beigene had 1 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Beigene and 13 mentions for Lantheus. Lantheus' average media sentiment score of 1.61 beat Beigene's score of 0.54 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beigene
0 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
12 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Lantheus has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beigene$3.81B6.28-$881.71M-$6.14-39.50
Lantheus$1.53B4.55$326.66M$4.3723.34

Lantheus has a net margin of 28.57% compared to Beigene's net margin of -25.94%. Lantheus' return on equity of 44.29% beat Beigene's return on equity.

Company Net Margins Return on Equity Return on Assets
Beigene-25.94% -25.12% -14.95%
Lantheus 28.57%44.29%23.52%

48.5% of Beigene shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 1.5% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beigene currently has a consensus target price of $316.67, indicating a potential upside of 30.55%. Lantheus has a consensus target price of $129.43, indicating a potential upside of 26.88%. Given Beigene's higher probable upside, equities research analysts clearly believe Beigene is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beigene
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lantheus
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lantheus received 337 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 66.02% of users gave Lantheus an outperform vote while only 62.50% of users gave Beigene an outperform vote.

CompanyUnderperformOutperform
BeigeneOutperform Votes
5
62.50%
Underperform Votes
3
37.50%
LantheusOutperform Votes
342
66.02%
Underperform Votes
176
33.98%

Summary

Lantheus beats Beigene on 11 of the 17 factors compared between the two stocks.

Remove Ads
Get Lantheus News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$6.99B$2.30B$5.34B$7.61B
Dividend YieldN/A0.78%5.11%4.33%
P/E Ratio16.976.0721.6717.80
Price / Sales4.5545.42375.2393.77
Price / Cash11.9815.7538.1534.64
Price / Book8.572.916.403.98
Net Income$326.66M-$65.73M$3.20B$247.24M
7 Day Performance6.87%0.98%5.58%5.40%
1 Month Performance0.90%-16.07%-7.19%-6.18%
1 Year Performance67.81%-21.79%7.89%-2.20%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNTH
Lantheus
4.3994 of 5 stars
$102.13
+0.1%
$129.43
+26.7%
+67.8%$6.99B$1.53B16.99700Positive News
ONC
Beigene
2.257 of 5 stars
$220.31
-7.6%
$310.40
+40.9%
N/A$21.74B$3.81B-26.7410,600Gap Down
BNTX
BioNTech
2.5235 of 5 stars
$86.64
-1.6%
$143.44
+65.6%
+11.6%$20.79B$2.75B-41.263,080Positive News
Gap Up
TEVA
Teva Pharmaceutical Industries
2.9882 of 5 stars
$13.91
+0.8%
$23.43
+68.5%
+0.9%$15.77B$16.54B-9.5936,800Options Volume
Positive News
ITCI
Intra-Cellular Therapies
3.4982 of 5 stars
$131.87
flat
$106.23
-19.4%
N/A$14.05B$680.50M-151.57560Analyst Forecast
Positive News
SMMT
Summit Therapeutics
2.6154 of 5 stars
$17.29
-0.4%
$35.40
+104.8%
+534.1%$12.75B$700,000.00-61.73110Gap Up
GMAB
Genmab A/S
4.2241 of 5 stars
$18.21
-1.0%
$41.33
+127.0%
-35.7%$12.05B$21.53B10.461,660Short Interest ↓
Gap Down
High Trading Volume
RDY
Dr. Reddy's Laboratories
3.0786 of 5 stars
$12.59
+1.8%
$17.00
+35.1%
-7.5%$10.51B$311.31B20.0424,800Positive News
High Trading Volume
MRNA
Moderna
4.2556 of 5 stars
$25.64
+2.1%
$59.00
+130.1%
-75.1%$9.91B$3.20B-2.763,900Positive News
Gap Up
VTRS
Viatris
2.7984 of 5 stars
$7.61
-0.1%
$10.50
+37.9%
-33.5%$9.09B$14.74B-10.2937,000
QGEN
Qiagen
3.496 of 5 stars
$40.33
+5.4%
$47.71
+18.3%
+7.5%$8.96B$1.98B112.296,030High Trading Volume
Remove Ads

Related Companies and Tools


This page (NASDAQ:LNTH) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners